. 2023 Jan 3;11(1):120. doi: 10.3390/vaccines11010120

Table 2.

Relationship between reactogenicity and antibody response after the mRNA-1273 vaccine.

Type of AE	SARS-CoV-2 Antibody Assay		Participants with AEs after 1st Dose		p-Value	Participants with AEs after 2nd Dose		p-Value
Type of AE	SARS-CoV-2 Antibody Assay		No	Yes	p-Value	No	Yes	p-Value
Any local AE	Anti-S IgG (U/mL)	T1	N = 3	N = 174	0.332
		T1	274.92 (48.00–1575.07)	176.77 (157.65–198.20)	0.332
		T2	N = 3	N = 168	0.394	N = 7	N = 164	0.658
		T2	3435.58 (1395.40–8460.58)	4428.94 (4096.38–4788.51)	0.394	4054.15	4424.86 (4090.72–4787.40)	0.658
	ND₅₀	T1	N = 2	N = 98	0.66
		T1	652.38 (0.001–534195223)	476.87 (391.29–581.17)	0.66
		T2	N = 2	N = 98	0.938	N = 1	N = 99	0.967
		T2	2962.78 (24.46–358921.93)	2849.71 (2474.00–3282.46)	0.938	2934.95	2851.02 (2477.42–3434.79)	0.967
Injection site pain	Anti-S IgG (U/mL)	T1	N = 7	N = 170	0.263
		T1	244.74 (145.64–411.24)	175.75 (156.42–197.51)	0.263
		T2	N = 7	N = 164	0.765	N = 10	N = 161	0.836
		T2	4166.77 (3113.15–5576-99)	4419.77 (4081.31–4787.40)	0.765	4267.76 (3067.61–5937.45)	4418.76 (4078.50–4786.30)	0.836
	ND₅₀	T1	N = 4	N = 96	0.373
		T1	310.89 (44.33–2184.74)	488.65 (400.50–596.21)	0.373
		T2	N = 4	N = 96	0.957	N = 2	N = 98	0.912
		T2	2798.98 (1629.67–4807.29)	2854.30 (2470.59–3296.86)	0.957	3011.62 (2171.20–4177.34)	2848.39 (2472.29–3282.46)	0.912
Injection site redness/ swelling	Anti-S IgG (U/mL)	T1	N = 150	N = 27	0.206
		T1	181.97 (159.81–207.25)	157.91 (131.46–189.71)	0.206
		T2	N = 144	N = 27	0.762	N = 133	N = 38	0.213
		T2	4432.00 (4088.96–4807.29)	4290.42 (3377.54–5450.04)	0.762	4296.35 (3946.39–4676.27)	4830.59 (4018.83–5804.97)	0.213
	ND₅₀	T1	N = 80	N = 20	0.454
		T1	462.38 (367.45–581.70)	557.06 (382.65–810.96)	0.454
		T2	N = 80	N = 20	0.664	N = 75	N = 25	0.153
		T2	2808.67 (2386.16–3305.98)	3031.80 (2329.16–3947.30)	0.664	3022.04 (2569.21–3553.86)	2397.18 (1818.86–3158.64)	0.153
Injection site motion limitation	Anti-S IgG (U/mL)	T1	N = 19	N = 158	0.758
		T1	187.46 (131.95–266.32)	177.01 (156.82–199.76)	0.758
		T2	N = 19	N = 152	0.138	N = 19	N = 152	0.535
		T2	3743.69 (3111.72–4504.02)	4500.91 (4140.00–4892.15)	0.138	4116.23 (3269.64–5183.22)	4447.34 (4095.43–4829.48)	0.535
	ND₅₀	T1	N = 8	N = 92	0.696
		T1	420.53 (154.06–1147.63)	485.51 (396.64–594.16)	0.696
		T2	N = 8	N = 92	0.919	N = 4	N = 96	0.891
		T2	2783.56 (1886.69–4105.82)	2857.59 (2462.63–3316.65)	0.919	2990.20 (659.63–13551.89)	2846.43 (2472.86–3276.42)	0.891
Any systemic AE	Anti-S IgG (U/mL)	T1	N = 22	N = 155	0.769
		T1	186.29 (132.65–261.64)	176.97 (156.71–199.80)	0.769
		T2	N = 22	N = 149	0.758	N = 8	N = 163	0.46
		T2	4273.66 (3506.71–5208.35)	4429.96 (4071.93–4819.48)	0.758	3869.90 (2622.41–5710.84)	4438.13 (4099.21–4803.97)	0.46
	ND₅₀	T1	N = 12	N = 88	0.417
		T1	385.57 (175.15–848.79)	494.42 (403.92–605.34)	0.417
		T2	N = 12	N = 88	0.06	N = 2	N = 98	0.912
		T2	1998.02 (1256.90–3176.14)	2993.64 (2588.81–3461.78)	0.06	3011.62 (2171.20–4177.34)	2848.39 (2472.29–3282.46)	0.912
Fever (≥37.5 °C)	Anti-S IgG (U/mL)	T1	N = 139	N = 38	0.764
		T1	179.72 (157.58–204.97)	172.31 (137.09–216.52)	0.764
		T2	N = 136	N = 35	0.056	N = 46	N = 125	0.056
		T2	4245.22 (3900.32–4621.68)	5108.58 (4259.91–6124.91)	0.056	3899.42 (3316.65–4584.58)	4613.18 (4228.63–5032.69)	0.056
	ND₅₀	T1	N = 79	N = 21	0.227
		T1	451.13 (360.08–565.20)	605.62 (400.50–916.01)	0.227
		T2	N = 79	N = 21	0.866	N = 22	N = 78	0.842
		T2	2834.00 (2414.90–3326.60)	2918.77 (2162.72–3939.13)	0.866	2777.15 (2071.57–3723.92)	2873.43 (2445.68–3375.20)	0.842
Chills	Anti-S IgG (U/mL)	T1	N = 140	N = 37	0.309
		T1	183.53 (161.36–208.74)	158.93 (124.17–203.38)	0.309
		T2	N = 137	N = 34	0.658	N = 50	N = 121	0.117
		T2	4371.19 (4002.21–4775.29)	4565.62 (3885.08–5365.37)	0.658	4008.67 (3434.00–4679.51)	4586.70 (4197.59–5011.87)	0.117
	ND₅₀	T1	N = 79	N = 21	0.267
		T1	453.42 (362.41–567.28)	594.43 (387.61–911.59)	0.267
		T2	N = 79	N = 21	0.698	N = 24	N = 76	0.731
		T2	2811.90 (2407.13–3284.73)	3007.46 (2148.33–4210.17)	0.698	2731.49 (2128.63–3505.10)	2890.68 (2444.56–3419.01)	0.731
Headache	Anti-S IgG (U/mL)	T1	N = 121	N = 56	0.266
		T1	170.49 (148.15–196.25)	195.66 (161.18–237.52)	0.266
		T2	N = 117	N = 54	0.034	N = 51	N = 120	0.212
		T2	4168.69 (3796.65–4577.20)	4979.66 (4353.11–5696.39)	0.034	4091.66 (3483.37–4805.07)	4551.98 (4173.50–4964.78)	0.212
	ND₅₀	T1	N = 72	N = 28	0.399
		T1	455.41 (358.53–581.70)	549.16 (396.10–761.20)	0.399
		T2	N = 72	N = 28	0.399	N = 25	N = 75	0.99
		T2	2747.89 (2329.7–3241.90)	3136.90 (2395.52–4106.77)	0.399	2847.08 (2099.91–3861.00)	2852.99 (2433.32–3345.80)	0.99
Muscle pain	Anti-S IgG (U/mL)	T1	N = 47	N = 130	0.401
		T1	193.02 (160.10–232.65)	172.98 (150.42–198.93)	0.401
		T2	N = 46	N = 125	0.676	N = 30	N = 141	0.958
		T2	4308.24 (3837.96–4837.27)	4447.34 (4035.52–4901.17)	0.676	4425.88 (3809.78–5141.62)	4405.55 (4032.74–4813.93)	0.958
	ND₅₀	T1	N = 26	N = 74	0.162
		T1	379.75 (237.41–607.30)	521.07 (421.50–644.17)	0.162
		T2	N = 26	N = 74	0.018	N = 9	N = 91	0.949
		T2	2159.73 (1715.54–2718.94)	3144.13 (2661.95–3713.64)	0.018	2870.12 (2396.07–3438.75)	2849.71 (2447.37–3318.18)	0.949
Fatigue	Anti-S IgG (U/mL)	T1	N = 73	N = 104	0.576
		T1	185.05 (157.80–217.02)	173.34 (147.84–203.24)	0.576
		T2	N = 72	N = 99	0.593	N = 37	N = 134	0.885
		T2	4519.60 (4017.91–5082.76)	4331.12 (3905.71–4803.97)	0.593	4362.14 (3634.96–5234.80)	4422.83 (4058.82–4818.37)	0.885
	ND₅₀	T1	N = 39	N = 61	0.902
		T1	472.61 (356.78–626.04)	484.62 (368.81–636.94)	0.902
		T2	N = 39	N = 61	0.69	N = 18	N = 82	0.868
		T2	2752.96 (2195.84–3452.23)	2916.76 (2433.88–3494.62)	0.69	2780.99 (1957.49–3951.85)	2867.48 (2456.97–3346.57)	0.868
Joint pain	Anti-S IgG (U/mL)	T1	N = 160	N = 17	0.46
		T1	175.63 (155.52–198.34)	202.91 (147.84–278.48)	0.46
		T2	N = 155	N = 16	0.298	N = 126	N = 45	0.481
		T2	4352.11 (4015.13–4717.37)	5004.95 (3778.33–6629.79)	0.298	4337.11 (3948.21–4765.41)	4617.43 (4045.76–5271.08)	0.481
	ND₅₀	T1	N = 92	N = 8	0.352
		T1	466.98 (380.72–572.80)	657.05 (277.27–1557.04)	0.352
		T2	N = 92	N = 8	0.886	N = 72	N = 28	0.639
		T2	2843.15 (2456.97–3290.03)	2951.89 (1661.50–5243.24)	0.886	2793.83 (2365.92–3298.37)	3006.77 (2298.79–3932.78)	0.639
Vomiting	Anti-S IgG (U/mL)	T1	N = 174	N = 3	0.267
		T1	179.60 (160.10–201.42)	109.42 (43.590 274.73)	0.267
		T2	N = 168	N = 3	0.646	N = 155	N = 16	0.386
		T2	4419.77 (4086.96–4779.69)	3853.90 (2535.71–5858.68)	0.646	4457.59 (4105.82–4839.49)	3967.35 (3168.11–4967.07)	0.386
	ND₅₀	T1	N = 98	N = 2	0.649
		T1	476.87 (390.30–582.51)	659.02 (97.54–4451.43)	0.649
		T2	N = 98	N = 2	0.321	N = 90	N = 10	0.549
		T2	2880.71 (2506.11–3310.55)	1748.24 (0.07–41409501)	0.321	2811.90 (2426.61–3258.37)	3236.68 (1976.97–5299.07)	0.549
Rash	Anti-S IgG (U/mL)	T1	N = 164	N = 13	0.872
		T1	178.57 (158.60–201.00)	172.31 (110.71–268.16)	0.872
		T2	N = 158	N = 13	0.688	N = 160	N = 11	0.548
		T2	4428.94 (4099.21–4786.30)	4173.50 (2720.19–6404.72)	0.688	4382.28 (4045.76–4746.79)	4822.81 (3450.64–6742.17)	0.548
	ND₅₀	T1	N = 92	N = 8	0.16
		T1	460.57 (375.06–565.46)	770.19 (365.76–1622.18)	0.16
		T2	N = 92	N = 8	0.558	N = 91	N = 9	0.516
		T2	2886.69 (2494.59–3340.41)	2479.70 (1410.26–4360.14)	0.558	2893.34 (2490.00–3362.02)	2465.47 (1758.73–3455.41)	0.516

Data are presented as geometric mean titers (95% confidence interval). AE, adverse event; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; IgG, immunoglobulin G; ND₅₀, median neutralizing titer.